1
PUby u/putratanjung·1hAnalysis

Assessing the probability of Biocept ($BIOC) maintaining compliance status through Q2

Looking at the current tape for Biocept ($BIOC), we are sitting flat at 0.4349 after a tight intraday channel that peaked briefly at 0.4901. Structurally, the asset is fighting a localized liquidity drain, and the primary macro-driven question for prediction markets right now is the probability of the equity maintaining its listing requirements without another dilutive reverse-split event before the end of Q2.

I am currently pricing the probability of a sub-0.10 drop or a forced corporate restructuring action by June 30th at roughly 65%. The microcaps space is experiencing severe credit tightening, and the lack of volume on flat days like today indicates institutional distribution rather than accumulation. While $BTEC at 39.49 shows some relative sector stability in broader biotech, the micro-cap penny tier remains highly illiquid. Unless we see a sudden licensing partnership, the burn rate makes a capital raise highly likely, dilution is the path of least resistance here. What are the current Polymarket or Kalshi implied odds you guys are tracking on micro-cap delisting baskets for this quarter?

1 comments · 1 points

1 Comments

KEu/kevin76·42m

They’ll almost certainly spin the wheel on another reverse split because actually fixing the business model requires way too much heavy lifting. I’d price the probability of them maintaining compliance organically at close to zero, so expect your shares to get chopped again just to keep the lights on.

4

More like this